Adalimumab biosimilar (Eastern Biotech)

阿达木单抗生物类似药（东方百泰生物）

Report date: 2025/07/09 20:00:48

Base Information

Drug NameAdalimumab biosimilar (Eastern Biotech)

Drug Alias NameRecombinant human anti-tumor necrosis factor α (TNFα) monoclonal antibody (Eastern Biotech)阿达木单抗生物仿制药（东方百泰生物）重组抗TNFa全人单抗（东方百泰生物）JY-026

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsPsoriasisCrohn DiseaseArthritis, Rheumatoid +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusIND

Highest Status in ChinaIND

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsPsoriasisCrohn DiseaseArthritis, Juvenile

Inactive IndicationsArthritis, RheumatoidSpondylitis, Ankylosing

ATC CodeL04AB04